InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,829.20
(
0.96%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
-0.64%
)
Bitcoin
56,590.01
(
-0.69%
)
Post# of 26138
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Just the facts maam

Send PM Follow Ignore
Followers 20
Posts 5392
Boards Moderated 0
Alias Born 01/04/2012

Just the facts maam

Re: None

Sunday, 03/04/2012 2:00:26 PM

Sunday, March 04, 2012 2:00:26 PM

Post# of 26138
Interesting theory on early trial buyouts posted by Drugexpert of yahoo board on 28-Feb-12 11:40 am

Why BPAX is strong buyout target

Phase I, II, III etc are secondary not the core things. If the drug's theory and design are correct , technological implementation is correct - then it will work no matter which phase it is in. That's the main point & key to success. GVAX Pancreas cancer vaccine, Phase 1B showing strong performance which means the drug is designed and developed in right way. No brainer it will show strong performance in Pahse II and III. Exactly for this reason Bristol Mayers bought INHX for $2.5B for its Phase-II HepC drug.

BPAX will be winner. Huge multibagger in few months.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up